

**Ahmedabad**  
**21.1.2005**

**PRESS RELEASE**

---

**HESTER PHARMA registers a growth of 348% in Net Profit and 120% in Sales**

---

Hester Pharmaceuticals Limited is a leading biotech company, manufacturing poultry vaccines in Ahmedabad, India.

Hester's Net Profit for the 9 months ended 31.12.2004 is recorded at Rs. 2.94 crores as compared to Rs. 0.66 crores for the previous corresponding period.

Hester has reported a turnover of Rs. 11.26 crores for the 9 months ended 31.12.2004 against Rs. 5.11 crores for the previous corresponding period.

On an equity of Rs. 3.53 crores (35.30 lac shares of Rs. 10 each), EPS has gone up to Rs. 8.34 as on 31.12.2004 from Rs. 1.86 as on 31.12.2003.

Hester's growth mainly comes from export substitution of poultry vaccines.

Hester produces 39 types of poultry vaccines, thereby having the largest range of poultry vaccines in India.

Hester's 'GUMBORO I+' a live virus vaccine against Gumboro disease has registered a growth of 55% in sales in this 9 months period as compared to the previous corresponding 9 months. GUMBORO I+ vaccine has been developed indigenously.

Besides producing poultry vaccines, Hester exclusively represents Merial Inc., USA, for Merial's range of poultry vaccines. Merial is the worlds largest company in animal health business, having a worldwide turnover of over Rs. 8000 crores.

**Rajiv Gandhi**  
**Managing Director**  
**Hester Pharmaceuticals Limited**  
**[www.hesterpharma.co.in](http://www.hesterpharma.co.in)**  
**[rajiv@hesterpharma.co.in](mailto:rajiv@hesterpharma.co.in)**